These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21471980)

  • 1. Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.
    Tajima Y; Saito S; Ohno K; Tsukimura T; Tsujino S; Sakuraba H
    J Hum Genet; 2011 Jun; 56(6):440-6. PubMed ID: 21471980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.
    Yoshimizu M; Tajima Y; Matsuzawa F; Aikawa S; Iwamoto K; Kobayashi T; Edmunds T; Fujishima K; Tsuji D; Itoh K; Ikekita M; Kawashima I; Sugawara K; Ohyanagi N; Suzuki T; Togawa T; Ohno K; Sakuraba H
    Clin Chim Acta; 2008 May; 391(1-2):68-73. PubMed ID: 18328816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.
    Okumiya T; Kroos MA; Vliet LV; Takeuchi H; Van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2007 Jan; 90(1):49-57. PubMed ID: 17095274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.
    Parenti G; Zuppaldi A; Gabriela Pittis M; Rosaria Tuzzi M; Annunziata I; Meroni G; Porto C; Donaudy F; Rossi B; Rossi M; Filocamo M; Donati A; Bembi B; Ballabio A; Andria G
    Mol Ther; 2007 Mar; 15(3):508-14. PubMed ID: 17213836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
    Flanagan JJ; Rossi B; Tang K; Wu X; Mascioli K; Donaudy F; Tuzzi MR; Fontana F; Cubellis MV; Porto C; Benjamin E; Lockhart DJ; Valenzano KJ; Andria G; Parenti G; Do HV
    Hum Mutat; 2009 Dec; 30(12):1683-92. PubMed ID: 19862843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.
    Sugawara K; Tajima Y; Kawashima I; Tsukimura T; Saito S; Ohno K; Iwamoto K; Kobayashi T; Itoh K; Sakuraba H
    Mol Genet Metab; 2009 Apr; 96(4):233-8. PubMed ID: 19181556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.
    Tsukimura T; Chiba Y; Ohno K; Saito S; Tajima Y; Sakuraba H
    Mol Genet Metab; 2011 May; 103(1):26-32. PubMed ID: 21353612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.
    Sugawara K; Saito S; Sekijima M; Ohno K; Tajima Y; Kroos MA; Reuser AJ; Sakuraba H
    J Hum Genet; 2009 Jun; 54(6):324-30. PubMed ID: 19343043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546G>T mutation.
    Shimada Y; Kobayashi H; Kawagoe S; Aoki K; Kaneshiro E; Shimizu H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2011 Dec; 104(4):566-73. PubMed ID: 21982629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilising normal and mis-sense variant alpha-glucosidase.
    Kakavanos R; Hopwood JJ; Lang D; Meikle PJ; Brooks DA
    FEBS Lett; 2006 Aug; 580(18):4365-70. PubMed ID: 16846599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
    Shimada Y; Nishida H; Nishiyama Y; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
    Biochem Biophys Res Commun; 2011 Nov; 415(2):274-8. PubMed ID: 22027144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic structure-activity study on potential chaperone lead compounds for acid α-glucosidase.
    Bruckmann C; Repo H; Kuokkanen E; Xhaard H; Heikinheimo P
    ChemMedChem; 2012 Nov; 7(11):1943-53. PubMed ID: 22969039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A computational method to characterize the missense mutations in the catalytic domain of GAA protein causing Pompe disease.
    Thirumal Kumar D; Umer Niazullah M; Tasneem S; Judith E; Susmita B; George Priya Doss C; Selvarajan E; Zayed H
    J Cell Biochem; 2019 Mar; 120(3):3491-3505. PubMed ID: 30281819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
    Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
    Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".
    Tajima Y; Matsuzawa F; Aikawa SI; Okumiya T; Yoshimizu M; Tsukimura T; Ikekita M; Tsujino S; Tsuji A; Edmunds T; Sakuraba H
    J Hum Genet; 2007; 52(11):898-906. PubMed ID: 17805474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease.
    Roig-Zamboni V; Cobucci-Ponzano B; Iacono R; Ferrara MC; Germany S; Bourne Y; Parenti G; Moracci M; Sulzenbacher G
    Nat Commun; 2017 Oct; 8(1):1111. PubMed ID: 29061980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
    Parenti G; Zuppaldi A; Gabriela Pittis M; Rosaria Tuzzi M; Annunziata I; Meroni G; Porto C; Donaudy F; Rossi B; Rossi M; Filocamo M; Donati A; Bembi B; Ballabio A; Andria G
    Mol Ther; 2007 Mar; 15(3):508-514. PubMed ID: 28182897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.